|
The prognostic value of UHRF-1 and p53 in gastric cancer
Nalan A Babacan1, Hatice Reyhan Egilmez2, Birsen Yücel3, Parlak Ilknur4, Mehmet Metin Seker1, Turgut Kaçan1, Aykut Bahçeci1, Sener Cihan5, Bülent Akinci6, Berna Eriten2, Saadettin Kiliçkap7
1 Department of Medical Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey
2 Department of Pathology, Cumhuriyet University School of Medicine, Sivas, Turkey
3 Department of Radiation Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey
4 Department of Internal Medicine, Cumhuriyet University School of Medicine, Sivas, Turkey
5 Department of Medical Oncology, Okmeydanı Education and Research Hospital, İstanbul, Turkey
6 Department of Medical Oncology, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey
7 Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
Correspondence Address:
Dr. Nalan A Babacan
University of Marmara - Istanbul, PO Box TR-58140, Istanbul
Turkey
 Source of Support: The work was supported by grants from
Cumhuriyet University Scientific Research Project Unit (T.522), Conflict of Interest: None  | Check |
DOI: 10.4103/1319-3767.173755
Clinical trial registration T-522
|
|
Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis. Results: The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and fi ve (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132). Conclusion: According to this study, UHRF-1and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differantiating between gastric cancer and gastritis. |
